For now, various anti-MCL1 drugs are in early-phase development, including S64315 (also known as MIK665)—which demonstrated anti-MM activity in preclinical models, and is currently being evaluated in a phase I trial for RRMM (NCT02992483)—as well as AMG176, AMG397, and AZD5991, which are also being tested in phase I studies (NCT02675452, NCT03465540, and NCT03218683). Here, MCL1 is linked to Miyoshi myopathy.